Home

Getting Granular: Supply Chain Issues May Prompt Supplement ‘Finishing’ In-House
COVID-19 has been a blessing and a curse to many industries. There is no doubt that the current and future outlook for nutraceutical companies manufacturing capsules and tablets will continue to flourish, but what challenges still face this burgeoning market? Globally there is a tendency for manufacturers of finished dose nutraceuticals to rely on excipient providers and other Third Party organizations to granulate various components of their formulations. This over-reliance on outside parties ... read more
Switching from Batch to Continuous: Don’t Forget about Formulations
When pharma companies consider making the switch from batch processing to continuous manufacturing (CM), they often first think about machinery. But they shouldn’t forget about formulation. read more
Getting into the Mix: A Q&A on Nutraceuticals
Nutraceuticals production straddles the interface of food and pharmaceuticals manufacturing—two markets which themselves share plenty of overlap. Pharmaceutical customers often specify higher polish on product contact surfaces as well as exterior finishes that are more aesthetically pleasing. Their control systems often include features for running specific recipes and securely storing batch data. read more
You’ve Got Options: Choices Among Punch Heads, Barrels, and Tips—as well as in Die Shapes and Materials—Can Help Fine-Tune Tableting
The basics of rotary tablet compression tooling have stood the test of time. However, the specifications of tooling design have become more sophisticated. read more

Chronic Yeast Infection Therapy Trial Produces Positive Outcomes
June 23, 2022
Mycovia, a biopharmaceutical company, released topline results from evaluating VIVJOA™ (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC). Also known as ... read more
Long-Term Efficacy and Safety Data of Cenobamate Tablets Published
June 23, 2022
SK Life Science Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., a pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced that the results ... read more
FDA Approves Clorazepate Dipotassium Tablets USP
June 22, 2022
ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets. read more
Phase II Results of COVID-19 Therapy Published
June 22, 2022
Preliminary results of 60 Degrees Pharma’s phase II study of ARAKODA® (tafenoquine) for treatment of mild-moderate COVID-19 disease have been published in the peer-reviewed journal, New Microbes and ... read more
FDA Approves Congestive Heart Failure Medicine for Dogs
June 22, 2022
Boehringer Ingelheim Animal Health announced that the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) has granted conditional approval of VETMEDIN®-CA1 (pimobendan), which ... read more
Cremer Introduces Fast, Accurate Counting Machine for Gummies
June 21, 2022
Cremer, a supplier of product counting machines in the U.S., has introduced its HQS 1250 Counting & Dispensing Machine, designed specifically for gummy applications in the nutraceutical and ... read more
Exelixis Initiates Phase 3 Trial for Metastatic Colorectal Cancer Drug
June 21, 2022
Exelixis announced the initiation of STELLAR-303, a phase 3 trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not ... read more
Apotex Launches Generic Anticoagulant in Canada
June 21, 2022
Apotex Inc., a Canadian pharmaceutical manufacturer of generic medicines, announced the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis®. read more
Report: Tablet Coatings Prices Rising 2-5% Over Next Five Years
June 20, 2022
Tablet coating prices are projected to rise by 2-5% by 2026, according to a report by SpendEdge. The Tablet Coatings Market is expected to have a CAGR of 4.50% during 2022-2026. read more